Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Beam Therapeutics Inc
(NQ:
BEAM
)
23.65
-0.70 (-2.87%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Beam Therapeutics Inc
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
FDA Slaps CRISPR Cousin With A Hold; Beam Therapeutics Stock Collapses
August 01, 2022
The company didn't identify the reason behind the clinical hold in cancer treatment.
Via
Investor's Business Daily
Daily Biotech Pulse: Celyad Resumes Colorectal Cancer Trial, Setback For Otonomy, AstraZeneca Halts Phase 3 Head, Neck Cancer Trial
August 01, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
August 01, 2022
Via
Benzinga
Beam Therapeutics Shares Decline Following FDA's Clinical Hold On Leukemia Study
August 01, 2022
The U.S. Food and Drug Administration (FDA) has placed a clinical hold on Beam Therapeutics’ (NASDAQ: BEAM) Investigational New Drug (IND) application for the candidate BEAM-201 in the treatment of...
Via
Benzinga
Will a Recession Cause a Housing Crash in 2022?
July 27, 2022
For stock investors looking for real estate exposure, the market dislocation also provides many once-a-decade deals.
Via
InvestorPlace
BMO Capital Says Risk/Reward For This Gene Stock Assumes Clinical Success
June 17, 2022
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
April 08, 2022
During Friday's morning session, 234 stocks hit new 52-week lows. Interesting Facts About Today's 52-Week Lows: The largest company in terms of market cap...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
July 26, 2022
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
July 20, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Beyond Meat, Canoo, Veru And More: 12 Short Squeeze Candidates To Watch
July 20, 2022
One of the most powerful tradable market events is a short squeeze, so traders are always on the lookout for the next short squeeze candidate. S3 Partners analyst Ihor Dusaniwsky has just released a...
Via
Benzinga
Why Did BMO Capital Markets Raise Price Target For Gene Stock One Month After Initiating Coverage
July 18, 2022
Via
Benzinga
Expert Ratings For Beam Therapeutics
January 10, 2022
Within the last quarter, Beam Therapeutics (NASDAQ:BEAM) has observed the f...
Via
Benzinga
Hold Pfizer Today With Catalysts for Further Growth Tomorrow
July 18, 2022
Pfizer stock is down 12% in 2022. However, there is one short-term and one long-term catalyst that should inform your decision on whether PFE stock is right for your investment objectives.
Via
MarketBeat
Exposures
COVID-19
Product Safety
The Next CRISPR Is Here: How Verve Plans To Rival Amgen, Regeneron In Cholesterol
July 12, 2022
This could offer an improvement over CRISPR, which requires cutting DNA.
Via
Investor's Business Daily
The 3 Leaders of the Gene Editing Revolution
July 08, 2022
There's a wide field of gene editing stocks, but if you're looking for the best opportunities, there are a few likely winners to watch.
Via
InvestorPlace
7 Moonshot Investments Upending a $10 Trillion Industry
July 08, 2022
Gene editing is expensive at an estimated $5 billion per drug, but it could change the world in the very near future.
Via
InvestorPlace
Verve Therapeutics Amends Gene Editing Pact With Beam Therapeutics
July 07, 2022
Verve Therapeutics Inc (NASDAQ: VERV) entered into an amended and restated collaboration and license Agreement with Beam Therapeutics Inc (NASDAQ:
Via
Benzinga
Is Pfizer Stock A Buy Or A Sell As Its Covid Vaccine Faces A New Lawsuit?
July 05, 2022
The FDA's advisors recently backed Pfizer's Covid shot for young children.
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022
April 28, 2022
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
April 20, 2022
On Wednesday, 160 companies hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: Walt Disney (NYSE:DIS) was the largest firm by market cap to set a new...
Via
Benzinga
Stock Market Rebound Fizzles Amid Hawkish Fed; Taiwan Semiconductor Breaks Out, JPMorgan Tumbles: Weekly Review
January 14, 2022
A rebound from Monday's lows faded, with the key indexes all down for the week.
Via
Investor's Business Daily
The Journey To Rewrite Human DNA Is About To Get Wild, Thanks To Pfizer, Bayer, Intellia And Other CRISPR stocks
January 13, 2022
Big Pharma is paying attention to CRISPR stocks. Could that alight shares this year?
Via
Investor's Business Daily
Pfizer Continues Its Covid Makeover: What's Next For This Hot Stock?
January 13, 2022
How the pandemic continued a transformation Pfizer says began years ago.
Via
Investor's Business Daily
Biotech Bloodbath Continues Despite Gene-Editing Deals For Pfizer, Bayer
January 10, 2022
Pfizer and Bayer inked deals with several companies in gene-editing.
Via
Investor's Business Daily
Pfizer, Beam Ink Multi-Target Research Collaboration For In Vivo Base Editing Programs
January 10, 2022
Pfizer Inc (NYSE: PFE) and Beam Therapeutics Inc (NASDAQ: BEAM) have announced an exclusive four-year research collaboration focused on in vivo ...
Via
Benzinga
Pfizer Makes Foray Into CRISPR, Inking $1.35 Billion Deal With Beam Therapeutics
January 10, 2022
The companies hope to cure diseases of the liver, muscle and central nervous system.
Via
Investor's Business Daily
Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases
January 10, 2022
From
Pfizer Inc.
Via
Business Wire
Top 5 Moonshots for 2022 Countdown: My No. 5 Pick
December 22, 2021
2021 wasn't the best year for gene-editing stocks, but expect a comeback in 2022. Here's the top gene-editing choice for next year.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2022
January 05, 2022
Upgrades According to TD Securities, the prior rating for Canada Goose Holdings Inc (NYSE:
Via
Benzinga
Got $1,000? Check Out These 3 Top Biotech Stocks
December 03, 2021
Two big biotechs and one smaller one that could be winners over the long term.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.